Preclinical studies suggest that cyclooxygenase (COX)-2 may be involved in the molecular
pathogenesis of some types of lung cancer. Most of the available studies point to its …

Lung cancer accounts for more than 28% of all cancer deaths each year and is the leading
cause of cancer-related mortality in the USA [1]. Despite focused research in conventional …

Evidence is accumulating to suggest that the inducible isoenzyme of cyclooxygenase (COX)-
2 is up-regulated in human cancers and epidemiological studies indicate that COX inhibitors …

Lung cancer is the leading cause of cancer death in the United States. Although the low 5-
year survival rate (under 15%) has changed minimally in the last 25 years, new agents and …

Lung cancer is by far the leading cause of cancer-related death. Overall survival is poor and
has not improved substantially over the last half century. It is clear that new approaches are …

The beneficial effects of cyclo-oxygenase (COX) inhibitors in both colon cancer and
adenomatous polyps suggest a role for the prostanoid pathway in epithelial malignancy …

Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …

Abstract Cyclooxygenase (COX)-2 expression was immunohistochemically examined in 59
human lung cancers as well as in normal and premalignant lung specimens. In contrast to …

It is well accepted that an increase in the expression of cyclooxygenase-2 (COX-2), a key
inducible enzyme involved in the production of prostaglandins and other eicosanoids, may …

Lung cancer is the leading cause of cancer death in the USA. Conventional therapy using
chemotherapy, radiation therapy, and a combination of the two, has yielded modest …